Ranbaxy stock to stop trading on exchanges from next week

Shares of Ranbaxy Laboratories will stop trading on BSE and NSE with effect from April 6 onwards as the company is merging with Sun Pharmaceutical Industries in a USD 4 billion deal.

Ranbaxy ends last trading day on bright note; surges over 5%

Shares of Ranbaxy Laboratories on Wednesday ended with strong gains on the last day of its trade, as the company is being merged with Sun Pharmaceutical in a USD 4 billion deal.

Sun Pharma, Ranbaxy rise after regulatory nods for merger deal

At the end of today's trade, Sun Pharmaceutical Industries ended at Rs 1,039.85, up 1.55 percent and Ranbaxy Laboratories closed at Rs 819.55 apiece, up 1.86 percent.

Ranbaxy seeks to assuage shareholders' worries

Drug major Ranbaxy Laboratories Friday sought to assuage concerns of shareholders in the wake of company's stock price taking a hard knock after the US Food and Drug Administration banned the import of drugs from its Mohali plant.

Certain consent decree terms to apply to Mohali unit: Ranbaxy

"The FDA also ordered that the Mohali facility be subject to certain terms of the consent decree of permanent injunction entered against Ranbaxy in January 2012," according to United States Food and Drug Administration website.

US import alert on Ranbaxy; Mohali unit part of consent decree

"The firm will remain on the import alert until the company complies with U.S. Drug manufacturing requirements, known as current good manufacturing practices (CGMP)," USFDA said in a statement.

Ranbaxy falls about 30% after FDA import alert

A third Ranbaxy Laboratories plant in India has been sanctioned with an import alert ban from the US Food and Drug Administration, triggering the worst single day fall in its stock on Monday and a brokerage downgrade.

Ranbaxy shares dive over 9% after Daiichi says misled over probes

Following the weakness in the stock, the market value of the company slipped by Rs 1,527 crore to Rs 16,708 crore.

Ranbaxy recovers lost ground; shares end nearly 4% higher

Shares of Ranbaxy Laboratories recovered from early losses and settled nearly 4 percent higher on hopes that settlement of its long lawsuit in the US would be positive for drug maker the in the long term.